Literature DB >> 8085372

Toxin inactivation and antigen stabilization: two different uses of formaldehyde.

R Rappuoli1.   

Abstract

Since the 1920s, when Ramon discovered the detoxifying properties of formaldehyde, this compound has been used to inactivate toxins, whole bacterial cells and viruses. With the development of vaccines that are detoxified by genetic manipulation, formaldehyde has a new role as a stabilizer of such genetically detoxified antigens.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8085372     DOI： 10.1016/0264-410x(94)90259-3

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  15 in total

1.  Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.

Authors:  C M Ausiello; F Urbani; A la Sala; R Lande; A Cassone
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

2.  Caspase activation as a versatile assay platform for detection of cytotoxic bacterial toxins.

Authors:  Angela M Payne; Julie Zorman; Melanie Horton; Sheri Dubey; Jan ter Meulen; Kalpit A Vora
Journal:  J Clin Microbiol       Date:  2013-07-03       Impact factor: 5.948

3.  Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease.

Authors:  Eliud O Oloo; Jeremy A Yethon; Martina M Ochs; Bruce Carpick; Raymond Oomen
Journal:  J Biol Chem       Date:  2011-02-04       Impact factor: 5.157

4.  Detoxification of the Helicobacter pylori cytotoxin.

Authors:  R Manetti; P Massari; M Marchetti; C Magagnoli; S Nuti; P Lupetti; P Ghiara; R Rappuoli; J L Telford
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

5.  Development of a next-generation chikungunya virus vaccine based on the HydroVax platform.

Authors:  Dawn K Slifka; Hans-Peter Raué; Whitney C Weber; Takeshi F Andoh; Craig N Kreklywich; Victor R DeFilippis; Daniel N Streblow; Mark K Slifka; Ian J Amanna
Journal:  PLoS Pathog       Date:  2022-07-05       Impact factor: 7.464

6.  Oligomeric and subunit structure of the Helicobacter pylori vacuolating cytotoxin.

Authors:  P Lupetti; J E Heuser; R Manetti; P Massari; S Lanzavecchia; P L Bellon; R Dallai; R Rappuoli; J L Telford
Journal:  J Cell Biol       Date:  1996-05       Impact factor: 10.539

7.  Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.

Authors:  Benjamin K Quintel; Archana Thomas; Danae E Poer DeRaad; Mark K Slifka; Ian J Amanna
Journal:  Vaccine       Date:  2018-12-31       Impact factor: 3.641

8.  Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease.

Authors:  J Plana-Duran; M Bastons; M J Rodriguez; I Climent; E Cortés; C Vela; I Casal
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.

Authors:  T Schiffner; L Kong; C J A Duncan; J W Back; J J Benschop; X Shen; P S Huang; G B Stewart-Jones; J DeStefano; M S Seaman; G D Tomaras; D C Montefiori; W R Schief; Q J Sattentau
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

Review 10.  Review: Vaccine Myth-Buster - Cleaning Up With Prejudices and Dangerous Misinformation.

Authors:  Paul Löffler
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.